Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 43Breast Neoplasms 37Lymphoma, Large B-Cell, Diffuse 29Sarcoma 20Lymphoma, Non-Hodgkin 17Burkitt Lymphoma 16Neuroblastoma 15Leukemia 13HIV Infections 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Hodgkin Disease 11Acquired Immunodeficiency Syndrome 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Ovarian Neoplasms 9Multiple Myeloma 9Carcinoma, Hepatocellular 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Liver Neoplasms 8Liposarcoma 7Breast Neoplasms, Male 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Anaplastic 6Fallopian Tube Neoplasms 6Sarcoma, Kaposi 5Neoplasms, Plasma Cell 5Lymphoma, B-Cell 5Lung Neoplasms 5Histiocytoma, Malignant Fibrous 5Fibrosarcoma 5

Interventions

Vincristine 1Rituximab 1Prednisone 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × HIV Seropositivity × Doxorubicin × Clear all
NCT01092182 2023-04-27

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
194 enrolled 19 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, HIV Seropositivity, HIV Infections, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡